D. Foulkes and Medscape, “Eleven Years Disease-Free: Role of Chemotherapy in Metastatic BRCA2-Related Breast Cancer,” Nature Reviews. Clinical Oncology, Vol. 6, No. 8, 2009, pp. 488-492.Huang F, Kushner YB, Langleben A, et al. Eleven years disease-free: role of chemotherapy in ...
You have tested positive for mutations in the genes BRCA1 and BRCA2, which can increase the risk of a second cancer. The cancer is recurrent. Not all of the tissue surrounding the cancer was removed in a prior surgery. You have inflammatory breast cancer. The size of the tumor, in relat...
Treatment with (neo)adjuvant chemotherapy for breast cancer, as currently given, causes cell damage by induction of double-strand DNA breaks. Because BRCA1 and BRCA2 proteins play a role in the repair of DNA damage, the efficacy of (neo)adjuvant chemotherapy may be increased in BRCA1/2-assoc...
3 Bilateral salpingo-oophorectomy at 35–40 years of age is recommended for women with BRCA1 and BRCA2. The use of oral contraceptives is recommended until childbearing is complete.4, 5 The symptoms of ovarian cancer are nonspecific and often occur when the disease is already spread through...
The response of breast cancer to neoadjuvant chemotherapy (NAC) varies substantially, even when tumours belong to the same molecular or histological subtype1. Here we identify the oestrous cycle as an important contributor to this heterogeneity. In three
followed by 4 cycles of taxane and trastuzumab (P + EC-TH) regimen as neoadjuvant therapy for human epidermal growth factor receptor 2 (HER2) positive breast cancer and to investigate the predictive value of p53, p63, and epidermal growth factor receptor (EGFR) status for neoadjuvant ...
Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial. J Natl Cancer Inst. 2015;107(1):379. Article PubMed Google Scholar Cortejoso L, García-González X, García MI, García-Alfonso P, Sanjurjo M, López-Fernández ...
D. et al. BRCA1- and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II. Cancer Res. 67, 7078–7081 (2007). CAS PubMed Google Scholar Aratani, Y., Andoh, T. & Koyama, H. Effects of DNA topoisomerase inhibitors on nonhomologous and ...
In an exploratory subgroup analysis, durvalumab improved OS in patients with triple-negative breast cancer (TNBC; n = 82; HR: 0.54, 95% CI: 0.30–0.97, P = 0.0377). Exploratory analysis showed that the HR of death was 0.37 (95% CI: 0.12–1.13) for patients with PD-L1+ ...
et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 25, 846–859 (2014). Article CAS PubMed Google Scholar Mehta, A. K. et al. Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated ...